Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00210-021-02049-7 http://scihub22266oqcxt.onion/10.1007/s00210-021-02049-7 33443616!7807216!33443616     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Naunyn+Schmiedebergs+Arch+Pharmacol 2021 ; 394 (5): 1003-1007 Nephropedia Template TP {{tp|p=33443616|t=2021. Efficacy of synthetic glucocorticoids in COVID-19 endothelites |pdf=|usr=}}{{33443616}} gab.com Text Efficacy of synthetic glucocorticoids in COVID-19 endothelites JO: Naunyn Schmiedebergs Arch Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33443616 #FOAvip Since March 2020, the world has been fighting a global pandemic caused by a new coronavirus SARS-CoV-2 (COVID-19). SARS-CoV-2 is responsible for severe acute respiratory syndrome, an airway disease that can be severe and fatal in a percentage of cases. Patients with severe COVID-19 can develop extrapulmonary lesions, with renal, hepatic, cardiac, neurological, and tissue involvement that can cause further severe complications. On December 21, 2021, the European Medicines Agency (EMA) authorized the marketing of the first COVID-19 vaccine. However, several randomized trials are ongoing to find effective, safe, and widely available treatments. The most severe stages of COVID-19 infection are characterized by a multi-system inflammatory state induced by a cytokine storm causing multi-organ injury. Epidemiologic evidence has shown that glucocorticoids (GCs), particularly dexamethasone, are used in severe, hospitalized patients with COVID-19 with good therapeutic benefit. COVID-19 can also damage the endothelial system, causing microcirculatory disturbances and consequently leading to functional organ disorders. The combination of endothelial dysfunction with a generalized inflammatory state may contribute to the general pro-coagulative state described in patients with COVID-19 with increased risk of venous and arterial occlusions. The aim of this article is to describe the therapeutic utility of GCs in stabilizing the vascular endothelial barrier in COVID-19 infection. Indeed, we believe that the stabilization of the endothelial barrier and the anti-inflammatory effect of GCs could be the main effect underlying the therapeutic efficacy in COVID-19 patients. Twit Text FOAVip Efficacy of synthetic glucocorticoids in COVID-19 endothelites ????Naunyn Schmiedebergs Arch Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33443616 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33443616 #FOAvip English Wikipedia <ref>{{Cite pmid|33443616}}</ref> Efficacy of synthetic glucocorticoids in COVID-19 endothelites #MMPMID33443616 Ferrara F; Vitiello A Naunyn Schmiedebergs Arch Pharmacol 2021[May]; 394 (5): 1003-1007 PMID33443616show ga Since March 2020, the world has been fighting a global pandemic caused by a new coronavirus SARS-CoV-2 (COVID-19). SARS-CoV-2 is responsible for severe acute respiratory syndrome, an airway disease that can be severe and fatal in a percentage of cases. Patients with severe COVID-19 can develop extrapulmonary lesions, with renal, hepatic, cardiac, neurological, and tissue involvement that can cause further severe complications. On December 21, 2021, the European Medicines Agency (EMA) authorized the marketing of the first COVID-19 vaccine. However, several randomized trials are ongoing to find effective, safe, and widely available treatments. The most severe stages of COVID-19 infection are characterized by a multi-system inflammatory state induced by a cytokine storm causing multi-organ injury. Epidemiologic evidence has shown that glucocorticoids (GCs), particularly dexamethasone, are used in severe, hospitalized patients with COVID-19 with good therapeutic benefit. COVID-19 can also damage the endothelial system, causing microcirculatory disturbances and consequently leading to functional organ disorders. The combination of endothelial dysfunction with a generalized inflammatory state may contribute to the general pro-coagulative state described in patients with COVID-19 with increased risk of venous and arterial occlusions. The aim of this article is to describe the therapeutic utility of GCs in stabilizing the vascular endothelial barrier in COVID-19 infection. Indeed, we believe that the stabilization of the endothelial barrier and the anti-inflammatory effect of GCs could be the main effect underlying the therapeutic efficacy in COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |COVID-19/*complications[MESH] |Cytokine Release Syndrome/drug therapy/etiology[MESH] |Dexamethasone/therapeutic use[MESH] |Endothelium, Vascular/*physiopathology[MESH] |Glucocorticoids/*therapeutic use[MESH] |Humans[MESH] |Randomized Controlled Trials as Topic[MESH]Efficacy of synthetic glucocorticoids in COVID-19 endothelites (epmc).pdf DeepDyve Pubget Overpricing